Template:Anticholinergic Toxicity Treatement: Difference between revisions
Ostermayer (talk | contribs) |
Ostermayer (talk | contribs) (Prepared the page for translation) |
||
| Line 1: | Line 1: | ||
<languages/> | |||
<translate> | |||
==Treatment== | ==Treatment== | ||
*Consider GI decon with [[Activated Charcoal]] if patient presents <2 hours after ingestion and remains cooperative | |||
*Consider GI decon with [[Special:MyLanguage/Activated Charcoal|Activated Charcoal]] if patient presents <2 hours after ingestion and remains cooperative | |||
===Sedation=== | ===Sedation=== | ||
*Decreases the risk of [[hyperthermia]], [[rhabdo]], traumatic injuries | |||
*[[Benzos]] are agents of choice especially increase seizure threshold<ref>Burns MJ, et al. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med. 2000:35(4):374-381.</ref> | *Decreases the risk of [[Special:MyLanguage/hyperthermia|hyperthermia]], [[Special:MyLanguage/rhabdo|rhabdo]], traumatic injuries | ||
*[[Special:MyLanguage/Benzos|Benzos]] are agents of choice especially increase seizure threshold<ref>Burns MJ, et al. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med. 2000:35(4):374-381.</ref> | |||
**Repeat boluses every 5-15 minutes as needed to halt seizures and provide adequate sedation | **Repeat boluses every 5-15 minutes as needed to halt seizures and provide adequate sedation | ||
**Goal: QRS duration < 110 msec | **Goal: QRS duration < 110 msec | ||
===Cholinesterase inhibition=== | ===Cholinesterase inhibition=== | ||
*Indicated for severe agitation or delirium (esp if unresponsive to [[benzos]]) | |||
*Indicated for severe agitation or delirium (esp if unresponsive to [[Special:MyLanguage/benzos|benzos]]) | |||
*Contraindicated in QRS>100 or Na blockade signs (R' in aVR) and in narrow angle glaucoma | *Contraindicated in QRS>100 or Na blockade signs (R' in aVR) and in narrow angle glaucoma | ||
*Relatively contraindicated in asthma or ileus | *Relatively contraindicated in asthma or ileus | ||
*[[Physostigmine]] - strongly consider poison control consult before giving | *[[Special:MyLanguage/Physostigmine|Physostigmine]] - strongly consider poison control consult before giving | ||
**Crosses blood brain barrier, can be used to help make dx | **Crosses blood brain barrier, can be used to help make dx | ||
**Dosing: 0.5mg-1mg IV over 5min (repeat dosing up to 2mg in first hour)<ref>Rosenbaum C and Bird SB. Timing and frequency for physostigmine redosing for antimuscarininc toxicity. J Med Toxicol. 2010;6:386-92.</ref> | **Dosing: 0.5mg-1mg IV over 5min (repeat dosing up to 2mg in first hour)<ref>Rosenbaum C and Bird SB. Timing and frequency for physostigmine redosing for antimuscarininc toxicity. J Med Toxicol. 2010;6:386-92.</ref> | ||
| Line 18: | Line 26: | ||
**Stop infusion every 12 hours to determine resolution of the toxidrome | **Stop infusion every 12 hours to determine resolution of the toxidrome | ||
**Side effects: bradycardia, dysrhythmias, cholinergic excess<ref>Pentel P and Peterson CD. Aystole complicating physostigmine treatment of tricyclic antidepressant overdose. Ann Emerg Med. 1980 Nov;9(11):588-90.</ref> | **Side effects: bradycardia, dysrhythmias, cholinergic excess<ref>Pentel P and Peterson CD. Aystole complicating physostigmine treatment of tricyclic antidepressant overdose. Ann Emerg Med. 1980 Nov;9(11):588-90.</ref> | ||
**Always have [[atropine]] at the bedside for bradycardia or cholinergic excess</ref><ref>Nguyen TT, et al. Adverse events from physostigmine: an observational study. Am J Emerg Med. 2018;36:141-2.</ref> | **Always have [[Special:MyLanguage/atropine|atropine]] at the bedside for bradycardia or cholinergic excess</ref><ref>Nguyen TT, et al. Adverse events from physostigmine: an observational study. Am J Emerg Med. 2018;36:141-2.</ref> | ||
**'''Contraindicated''' in [[TCA toxicity]] (associated with cardiac arrest) and in the presence of bradycardia or AV block | **'''Contraindicated''' in [[Special:MyLanguage/TCA toxicity|TCA toxicity]] (associated with cardiac arrest) and in the presence of bradycardia or AV block | ||
===Other therapies=== | ===Other therapies=== | ||
*[[Sodium bicarbonate]] for conduction abnormalities (QRS prolongation) | |||
*[[Special:MyLanguage/Sodium bicarbonate|Sodium bicarbonate]] for conduction abnormalities (QRS prolongation) | |||
**2 mEq/kg bolus (typically 2-3 amps of bicarb) | **2 mEq/kg bolus (typically 2-3 amps of bicarb) | ||
**Begin continuous NaCO3 infusion at 250mL/hr if bolus effective | **Begin continuous NaCO3 infusion at 250mL/hr if bolus effective | ||
**Solution preparation = 1L D5W mixed with 3 ampules NaHCO3 | **Solution preparation = 1L D5W mixed with 3 ampules NaHCO3 | ||
</translate> | |||
Revision as of 09:02, 23 January 2026
Treatment
- Consider GI decon with Activated Charcoal if patient presents <2 hours after ingestion and remains cooperative
Sedation
- Decreases the risk of hyperthermia, rhabdo, traumatic injuries
- Benzos are agents of choice especially increase seizure threshold[1]
- Repeat boluses every 5-15 minutes as needed to halt seizures and provide adequate sedation
- Goal: QRS duration < 110 msec
Cholinesterase inhibition
- Indicated for severe agitation or delirium (esp if unresponsive to benzos)
- Contraindicated in QRS>100 or Na blockade signs (R' in aVR) and in narrow angle glaucoma
- Relatively contraindicated in asthma or ileus
- Physostigmine - strongly consider poison control consult before giving
- Crosses blood brain barrier, can be used to help make dx
- Dosing: 0.5mg-1mg IV over 5min (repeat dosing up to 2mg in first hour)[2]
- Onset of action: 5-10min
- If partial response, repeat x3
- If 3 or more administrations are needed over a 6-hour period, start IV infusion (bolus 1-2 mg followed by 1 mg/hour)
- Stop infusion every 12 hours to determine resolution of the toxidrome
- Side effects: bradycardia, dysrhythmias, cholinergic excess[3]
- Always have atropine at the bedside for bradycardia or cholinergic excess</ref>[4]
- Contraindicated in TCA toxicity (associated with cardiac arrest) and in the presence of bradycardia or AV block
Other therapies
- Sodium bicarbonate for conduction abnormalities (QRS prolongation)
- 2 mEq/kg bolus (typically 2-3 amps of bicarb)
- Begin continuous NaCO3 infusion at 250mL/hr if bolus effective
- Solution preparation = 1L D5W mixed with 3 ampules NaHCO3
- ↑ Burns MJ, et al. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med. 2000:35(4):374-381.
- ↑ Rosenbaum C and Bird SB. Timing and frequency for physostigmine redosing for antimuscarininc toxicity. J Med Toxicol. 2010;6:386-92.
- ↑ Pentel P and Peterson CD. Aystole complicating physostigmine treatment of tricyclic antidepressant overdose. Ann Emerg Med. 1980 Nov;9(11):588-90.
- ↑ Nguyen TT, et al. Adverse events from physostigmine: an observational study. Am J Emerg Med. 2018;36:141-2.